Latest News & Updates

Breaking News

13 minutes ago
Team Pharma Now

Eminence Business Media Announces 6th Annual Pharma GMP & Quality Management 2026 in Mumbai

Longeveron Inc. Announces Phase 2b Trial Results Published In Cell Stem Cell Showing Laromestrocel (LOMECEL-B®) Improved Physical Function In Frailty Patients At Nine Months

Simantini Singh Deo

Opus Genetics Announces U.S. Food And Drug Administration Acceptance Of Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% For The Treatment Of Presbyopia

Simantini Singh Deo

Japan’s Ministry of Health, Labour And Welfare Grants Orphan Drug Status To Rilzabrutinib After Positive Phase 2 Results In IgG4-Related Disease

Simantini Singh Deo

Septerna, Inc. Reports Strong Phase 1 Results For Oral MRGPRX2 NAM SEP-631, Sets Plan For Phase 2 Trials In Chronic Spontaneous Urticaria

Simantini Singh Deo

Other trending news you may like to read

Eminence Business Media Announces 6th Annual Pharma GMP & Quality Management 2026 in Mumbai

Eminence Business Media's 6th Annual Pharma GMP & Quality 2026 (April 23-24, Mumbai) advances GMP maturity, data integrity, and digital quality systems for pharma excellence.

Team Pharma Now

Longeveron Inc. Announces Phase 2b Trial Results Published In Cell Stem Cell Showing Laromestrocel (LOMECEL-B®) Improved Physical Function In Frailty Patients At Nine Months

LOMECEL-B boosts 6MWT by 63m at 9 months in Phase 2b frailty trial.

Simantini Singh Deo

Opus Genetics Announces U.S. Food And Drug Administration Acceptance Of Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% For The Treatment Of Presbyopia

FDA accepts Opus sNDA for phentolamine 0.75% in presbyopia.

Simantini Singh Deo

Japan’s Ministry of Health, Labour And Welfare Grants Orphan Drug Status To Rilzabrutinib After Positive Phase 2 Results In IgG4-Related Disease

Japan grants orphan status to rilzabrutinib for IgG4-RD.

Simantini Singh Deo